孟鲁司特钠用于急性发作期支气管哮喘患儿的临床效果及对CD_4~+CD_8~+及CD_4~+/CD_8~+水平的影响
|
摘要
目的:探讨孟鲁司特钠用于急性发作期支气管哮喘患儿的临床效果及对CD_4~+、CD_8~+及CD_4~+/CD_8~+水平的影响。方法:选择2015年6月至2018年6月我院接诊的76例急性发作期支气管哮喘患儿,采用随机数字表法分为观察组和对照组,各38例。对照组患儿给予常规吸氧、补液等治疗措施,观察组患儿在此基础上给予孟鲁司特钠进行治疗。比较两组治疗前后CD_4~+、CD_8~+及CD_4~+/CD_8~+水平、用力肺活量(FVC)、最大呼气峰流速(PEF)及第1秒用力呼气容积(FEV1)、症状评分的变化及症状改善时间。结果:治疗后,观察组CD_4~+、CD_4~+/CD_8~+水平均显著高于对照组[(39.25±7.15)%vs(32.87±6.38)%,(1.89±0.53) vs(1.37±0.54)](P <0.05),CD_8~+水平明显低于对照组[(25.06±8.04)%vs(30.54±6.26)%](P <0.05);观察组FVC、PEF及FEV1均高于对照组[(79.24±7.11)%vs(68.48±5.26)%,(1.40±0.44) L/s vs(1.17±0.34) L/s,(76.55±3.55)%vs(65.85±3.46)%](P <0.05);观察组症状缓解用时及体征消失用时均低于对照组[(3.34±0.75) d vs(5.64±1.05) d,(5.22±1.17) d vs(7.62±1.55) d](P<0.05);观察组患儿日间症状评分及夜间症状评分均低于对照组[(1.12±0.45)分vs(1.63±0.58)分,(1.16±0.46)分vs(2.03±0.75)分](P <0.05)。结论:给予急性发作期支气管哮喘患儿常规治疗的基础上,加以孟鲁司特钠进行治疗可有效改善患儿的免疫功能、肺功能,缩短治疗用时,疗效显著。
Objective: To explore the clinical effect of montelukast sodium in children with acute attack of bronchial asthma and its influence on CD_4~+,CD_8~+and CD_4~+/CD_8~+levels. Methods: 76 children with acute attack of bronchial asthma in our hospital from June 2015 to June 2018 were selected and randomly divided into observation group and control group,38 cases in each group. The control group was treated with routine oxygen inhalation and fluid replacement,while the observation group was treated with montelukast sodium. The levels of CD_4~+,CD_8~+,CD_4~+/CD_8~+,forced vital capacity(FVC),peak expiratory flow(PEF),forced expiratory volume(FEV1),changes of symptom score and improvement time of symptoms were compared between the two groups before and after treatment. Results: After treatment,the levels of CD_4~+,CD_4~+/CD_8~+in the immune function of the observation group were significantly higher than those of the control group [(39.25 ± 7.15) % vs(32.87±6.38) %,(1.89±0.53) vs(1.37±0.54) ](P <0.05),and the level of CD_8~+was significantly lower than that of the control group [(25.06 ± 8.04) % vs(30.54 ± 6.26) %](P < 0.05); The FVC,PEF and FEV1 in the observation group were higher than those in the control group [(79.24±7.11) % vs(68.48±5.26) %,(1.40±0.44) L/s vs(1.17±0.34) L/s,(76.55±3.55) % vs(65.85±3.46) %](P <0.05); The symptom relief,time and signs disappeared in the observation group,all lower than those in the control group[(3.34±0.75) d vs(5.64±1.05) d,(5.22±1.17) d vs(7.62±1.55) d](P<0.05); The daily symptom score and night symptom score of the observation group were lower than that of the control group [(1. 12 ± 0. 45)score vs(1.63±0.58) score,(1.16±0.46) score vs(2.03±0.75) score](P <0.05). Conclusion: On the basis of routine treatment for children with acute attack of bronchial asthma,montelukast sodium treatment can effectively improve the immune function and lung function of children,shorten the treatment time,and have a significant effect.
Objective: To explore the clinical effect of montelukast sodium in children with acute attack of bronchial asthma and its influence on CD_4~+,CD_8~+and CD_4~+/CD_8~+levels. Methods: 76 children with acute attack of bronchial asthma in our hospital from June 2015 to June 2018 were selected and randomly divided into observation group and control group,38 cases in each group. The control group was treated with routine oxygen inhalation and fluid replacement,while the observation group was treated with montelukast sodium. The levels of CD_4~+,CD_8~+,CD_4~+/CD_8~+,forced vital capacity(FVC),peak expiratory flow(PEF),forced expiratory volume(FEV1),changes of symptom score and improvement time of symptoms were compared between the two groups before and after treatment. Results: After treatment,the levels of CD_4~+,CD_4~+/CD_8~+in the immune function of the observation group were significantly higher than those of the control group [(39.25 ± 7.15) % vs(32.87±6.38) %,(1.89±0.53) vs(1.37±0.54) ](P <0.05),and the level of CD_8~+was significantly lower than that of the control group [(25.06 ± 8.04) % vs(30.54 ± 6.26) %](P < 0.05); The FVC,PEF and FEV1 in the observation group were higher than those in the control group [(79.24±7.11) % vs(68.48±5.26) %,(1.40±0.44) L/s vs(1.17±0.34) L/s,(76.55±3.55) % vs(65.85±3.46) %](P <0.05); The symptom relief,time and signs disappeared in the observation group,all lower than those in the control group[(3.34±0.75) d vs(5.64±1.05) d,(5.22±1.17) d vs(7.62±1.55) d](P<0.05); The daily symptom score and night symptom score of the observation group were lower than that of the control group [(1. 12 ± 0. 45)score vs(1.63±0.58) score,(1.16±0.46) score vs(2.03±0.75) score](P <0.05). Conclusion: On the basis of routine treatment for children with acute attack of bronchial asthma,montelukast sodium treatment can effectively improve the immune function and lung function of children,shorten the treatment time,and have a significant effect.
引文
[1]郑贵浪,吴家兴.孟鲁司特治疗儿童支气管哮喘的临床疗效及肺功能和细胞因子变化研究[J].中国全科医学,2015,18(12):1387~1389,1395.
[2]万春霞.益气固本汤联合穴位贴敷对儿童支气管哮喘疗效和免疫功能的影响[J].中国实验方剂学杂志,2015,21(9):180~183.
[3]刘怡.孟鲁司特钠联合信必可治疗儿童哮喘疗效观察[J].山东医药,2015,55(38):66~67.
[4]耿爽,高山,胡红玲,等.哮喘患者急性加重期滤泡辅助型T细胞的分化水平及临床意义[J].细胞与分子免疫学杂志,2015,31(10):1383~1386.
[5]梁慕华,郭莉阁.化痰活血通络方对急性发作期支气管哮喘患者肺功能、血清炎性因子及免疫功能的影响[J].辽宁中医杂志,2016,43(2):322~325.
[6]雷春霞,王石.匹多莫德联合孟鲁司特钠治疗儿童支气管哮喘的临床观察[J].中国药房,2016,27(29):4142~4144.
[7]彭锦芸,吴李勇,肖建宏,等.孟鲁司特钠片联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘的临床研究[J].中国临床药理学杂志,2017,33(24):2559~2561,2565.
[8]王洪源,钱俊峰.孟鲁司特钠对老年支气管哮喘患者血清血管内皮生长因子、转化生长因子β1的影响[J].中国老年学杂志,2018,38(6):1364~1366.
[9]李同林,刘蔺,周航.孟鲁司特钠片联合布地奈德福莫特罗对支气管哮喘患者临床预后及生化指标的影响分析[J].中国地方病防治杂志,2017,32(12):1408~1409.
[10]莫丽慧,钟丽花.孟鲁司特联合布地奈德治疗支气管哮喘患儿的临床观察[J].中国药房,2017,28(14):1981~1984.
[2]万春霞.益气固本汤联合穴位贴敷对儿童支气管哮喘疗效和免疫功能的影响[J].中国实验方剂学杂志,2015,21(9):180~183.
[3]刘怡.孟鲁司特钠联合信必可治疗儿童哮喘疗效观察[J].山东医药,2015,55(38):66~67.
[4]耿爽,高山,胡红玲,等.哮喘患者急性加重期滤泡辅助型T细胞的分化水平及临床意义[J].细胞与分子免疫学杂志,2015,31(10):1383~1386.
[5]梁慕华,郭莉阁.化痰活血通络方对急性发作期支气管哮喘患者肺功能、血清炎性因子及免疫功能的影响[J].辽宁中医杂志,2016,43(2):322~325.
[6]雷春霞,王石.匹多莫德联合孟鲁司特钠治疗儿童支气管哮喘的临床观察[J].中国药房,2016,27(29):4142~4144.
[7]彭锦芸,吴李勇,肖建宏,等.孟鲁司特钠片联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘的临床研究[J].中国临床药理学杂志,2017,33(24):2559~2561,2565.
[8]王洪源,钱俊峰.孟鲁司特钠对老年支气管哮喘患者血清血管内皮生长因子、转化生长因子β1的影响[J].中国老年学杂志,2018,38(6):1364~1366.
[9]李同林,刘蔺,周航.孟鲁司特钠片联合布地奈德福莫特罗对支气管哮喘患者临床预后及生化指标的影响分析[J].中国地方病防治杂志,2017,32(12):1408~1409.
[10]莫丽慧,钟丽花.孟鲁司特联合布地奈德治疗支气管哮喘患儿的临床观察[J].中国药房,2017,28(14):1981~1984.